Company intelligence / Profile preview

Hemerion Therapeutics

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Hemerion’s lead program combines the photosensitizer Pentalafen® with the Heliance® illumination device to destroy residual glioblastoma cells after surgical resection. The INDYGO feasibility study showed high tolerance and encouraging efficacy, with half of patients achieving progression-free survival beyond 17 months. The ongoing HTX‑GBM‑01 Phase 1/2 trial follows FDA IND clearance and Fast Track designation. Hemerion received Orphan Drug Designation in 2021, and Fast Track status by the FDA in early 2025. The approach could redefine standard of care by potentially removing the need for radiotherapy post-surgery.

Therapeutic areas: Oncology
Modalities: Drug-device combination therapyphotosensitizing small molecule (Pentalafen®)photonic illumination platform (Heliance®)
Industry: Biotech

Drug pipeline

1 asset

pentalafen

Partnerships

University of Lille / Lille University Hospital / Inserm [co-development partners for technology development and early trials]University of Pittsburgh Medical Center [clinical trial partner for US-based phase I/II study].

Beyond the preview

Go deeper on Hemerion Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemerion Therapeutics.